Nectin4-CD137

Nectin4-CD137 is a preclinical-stage bispecific antibody being developed by NovaRock Biotherapeutics for the treatment of solid tumors, specifically esophageal and bladder cancers. Utilizing the company's proprietary NovaTE technology platform, the antibody is engineered to simultaneously engage Nectin-4, a cell surface protein overexpressed in various malignancies, and CD137 (4-1BB), a co-stimulatory receptor found on activated T cells. This dual-targeting approach is intended to concentrate T-cell activation within the tumor microenvironment, thereby enhancing anti-tumor immune activity while potentially reducing the systemic side effects often associated with CD137 agonists.

Other names

Nectin-4 + CD137 bispecific antibodyNectin-4/CD137 bispecific antibody